Details for New Drug Application (NDA): 063322
✉ Email this page to a colleague
NDA 063322 describes PENTACEF, which is a drug marketed by Glaxosmithkline and is included in three NDAs. Additional details are available on the PENTACEF profile page.
The generic ingredient in PENTACEF is ceftazidime. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
The generic ingredient in PENTACEF is ceftazidime. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
Summary for 063322
| Tradename: | PENTACEF |
| Applicant: | Glaxosmithkline |
| Ingredient: | ceftazidime |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 063322
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 1GM/VIAL | ||||
| Approval Date: | Nov 7, 1995 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 2GM/VIAL | ||||
| Approval Date: | Nov 7, 1995 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
